1.045
price up icon3.47%   0.035
after-market Dopo l'orario di chiusura: 1.05 0.005 +0.48%
loading
Precedente Chiudi:
$1.01
Aprire:
$0.9781
Volume 24 ore:
8,017
Relative Volume:
0.15
Capitalizzazione di mercato:
$4.02M
Reddito:
-
Utile/perdita netta:
$-736.70K
Rapporto P/E:
-104.50
EPS:
-0.01
Flusso di cassa netto:
$-4.14M
1 W Prestazione:
-1.42%
1M Prestazione:
+15.65%
6M Prestazione:
-25.36%
1 anno Prestazione:
-60.96%
Intervallo 1D:
Value
$0.9781
$1.1216
Intervallo di 1 settimana:
Value
$0.9781
$1.1216
Portata 52W:
Value
$0.802
$3.13

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name
Nome
Xortx Therapeutics Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
XRTX's Discussions on Twitter

Confronta XRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
XRTX
Xortx Therapeutics Inc
1.045 4.02M 0 -736.70K -4.14M -0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie

pulisher
May 01, 2025

XORTX Therapeutics Delays Yearly Report Filing - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 28, 2025

XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Announces Grant of European Patent - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan

Apr 28, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail

Apr 11, 2025
pulisher
Apr 09, 2025

1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail

Apr 09, 2025
pulisher
Apr 01, 2025

XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks

Apr 01, 2025
pulisher
Mar 26, 2025

XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks

Mar 26, 2025
pulisher
Mar 19, 2025

XORTX Announces Update for Discussion with the FDA - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan

Mar 19, 2025
pulisher
Feb 24, 2025

Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan

Feb 24, 2025
pulisher
Feb 15, 2025

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com

Feb 15, 2025
pulisher
Jan 29, 2025

XORTX to Present at Microcap Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Jan 29, 2025
pulisher
Jan 24, 2025

XORTX Therapeutics Announces Auditor Transition - MSN

Jan 24, 2025
pulisher
Jan 22, 2025

XORTX Announces Change of Auditor - TipRanks

Jan 22, 2025
pulisher
Jan 21, 2025

XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan

Jan 17, 2025
pulisher
Jan 16, 2025

XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel

Jan 16, 2025
pulisher
Jan 15, 2025

Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel

Jan 15, 2025
pulisher
Jan 06, 2025

XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan

Jan 06, 2025

Xortx Therapeutics Inc Azioni (XRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Capitalizzazione:     |  Volume (24 ore):